PET-guided Assessment of Amyloid Clearance and Outcomes in a Real-World Cohort of Patients with Alzheimer Disease undergoing Anti-Amyloid Therapy
Jana Ivanidze, Jae Gardella, Ahlanna Olson, Shuo Mila Sun, Charlene Thomas, Oi Lee Wong, Brielle Intorcia, Joseph Moirano et al.. American Journal of Neuroradiology, 2026-04-29
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Thirty-two patients met inclusion criteria (lecanemab, N=15; donanemab, N=17). Significant Aβ reduction was observed across the cohort (median ΔCL 59.11; p < 0.001) as well as within each treatment group. Most patients meeting TRAC criteria achieved full or partial TRAC (26/29, 89.7%). Baseline Aβ burden, as well as cognitive outcomes, did not differ significantly across TRAC categories (p = 0.25). ΔCL was not significantly associated with APOE-ε4 status or ARIA occurrence. In adjusted analyses, greater global CL reduction was associated with greater MMSE improvement, particularly at lower baseline burden. Region-specific analyses demonstrated marked, highly significant decrease in Z-scores across all regions. Longitudinal Aβ-PET demonstrated substantial Aβ clearance following AAT in routine clinical practice. Aβ reduction was not significantly associated with baseline Aβ burden, ARIA, APOE-ε4 status. In adjusted analyses, greater Aβ reduction was associated with greater MMSE improvement. Our findings support Aβ-PET as a sensitive biomarker of biological treatment effect, while highlighting the complexity of linking Aβ clearance to short-term cognitive outcomes.
What this study adds
Evidence grade: Moderate
This is a follow-up (cohort) study of 15 participants. In 32 patients receiving lecanemab or donanemab in routine practice, PET scans showed substantial amyloid clearance, and greater amyloid reduction was associated with greater MMSE improvement in adjusted analyses. Reported effect size: 89.7%.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Ivanidze, J., Gardella, J., Olson, A., Sun, S. M., Thomas, C., Wong, O. L., et al. (2026). PET-guided Assessment of Amyloid Clearance and Outcomes in a Real-World Cohort of Patients with Alzheimer Disease undergoing Anti-Amyloid Therapy. American Journal of Neuroradiology. https://doi.org/10.3174/ajnr.a9387
Vancouver
Ivanidze J, Gardella J, Olson A, Sun SM, Thomas C, Wong OL, et al. PET-guided Assessment of Amyloid Clearance and Outcomes in a Real-World Cohort of Patients with Alzheimer Disease undergoing Anti-Amyloid Therapy. American Journal of Neuroradiology. 2026. doi:10.3174/ajnr.a9387. PMID: 42055956.
BibTeX
@article{ivanidze2026-42055956,
author = {Ivanidze, Jana and Gardella, Jae and Olson, Ahlanna and Sun, Shuo Mila and Thomas, Charlene and Wong, Oi Lee and Intorcia, Brielle and Moirano, Joseph and others},
title = {{PET-guided Assessment of Amyloid Clearance and Outcomes in a Real-World Cohort of Patients with Alzheimer Disease undergoing Anti-Amyloid Therapy}},
journal = {American Journal of Neuroradiology},
year = {2026},
doi = {10.3174/ajnr.a9387},
pmid = {42055956},
url = {https://doi.org/10.3174/ajnr.a9387}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Thirty-two patients met inclusion criteria (lecanemab, N=15; donanemab, N=17).
- Significant Aβ reduction was observed across the cohort (median ΔCL 59.11; p < 0.001) as well as within each treatment group.
- Most patients meeting TRAC criteria achieved full or partial TRAC (26/29, 89.7%).
- Baseline Aβ burden, as well as cognitive outcomes, did not differ significantly across TRAC categories (p = 0.25). ΔCL was not significantly associated with APOE-ε4 status or ARIA occurrence.
- In adjusted analyses, greater global CL reduction was associated with greater MMSE improvement, particularly at lower baseline burden.
Why it matters
In 32 patients receiving lecanemab or donanemab in routine practice, PET scans showed substantial amyloid clearance, and greater amyloid reduction was associated with greater MMSE improvement in adjusted analyses. This is a small real-world study, and it did not find that amyloid reduction was significantly linked to baseline amyloid burden, ARIA, or APOE-ε4 status.
New to this subject? Start with our plain-English guide: Genetics →
Study details
- Study designlongitudinal study
- Participants15
- Effect size89.7%
- Evidence strengthModerate
How this study scored 45/100
Published in a peer-reviewed journal, and it is a longitudinal study following the same people over time. Scored zero for randomized / blinded because the record does not state it. We have no data on senior author's track record and institution's track record, so those were left out: it earned 42 of the 93 points we could judge it on, which is 45 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (American Journal of Neuroradiology) |
| Journal's citation record | 2 / 4 | American Journal of Neuroradiology: journal h-index 182 (OpenAlex, 2026-10-29) |
| Study design | 7 / 12 | A longitudinal study following the same people over time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 1 / 4 | 15 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 0 / 7 | Cited 0 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.0 citations a year over 2 year(s) since 2026 |
| Impact for its field and year | 0 / 6 | Cited 0.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | — / 4 | OpenAlex's profile for last-listed author Sonja Blum holds only 7 work(s), too few to judge a track record — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | 0 / 3 | OpenAlex lists 0 institution(s) in 0 countries — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 42055956) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 42 / 93 | Scored on 18 of 20 parts. We have no data for the rest, so they are left out: 42 of the 93 points we could judge it on is 45 out of 100. |
| Total | 45 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Genetics from nearby years
Also tagged “machine”
834 studies in the library carry the topic tag “machine”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 834 tagged studies.